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Progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy (PEHO) syndrome is a rare Mendelian phenotype
comprising severe retardation, early onset epileptic seizures, optic nerve/cerebellar atrophy, pedal oedema, and early death.
Atypical cases are often known as PEHO-like, and there is an overlap with ‘early infantile epileptic encephalopathy’. PEHO is
considered to be recessive, but surprisingly since initial description in 1991, no causative recessive gene(s) have been described.
Hence, we report a multiplex consanguineous family with the PEHO phenotype where affected individuals had a homozygous
frame-shift deletion in CCDC88A (c.2313delT, p.Leu772ter). Analysis of cDNA extracted from patient lymphocytes unexpectedly
failed to show non-sense mediated decay, and we demonstrate that the mutation produces a truncated protein lacking the crucial
C-terminal half of CCDC88A (girdin). To further investigate the possible role of CCDC88A in human neurodevelopment we re-
examined the behaviour and neuroanatomy of Ccdc88a knockout pups. These mice had mesial-temporal lobe epilepsy, micro-
cephaly and corpus callosum deﬁciency, and by postnatal Day 21, microcephaly; the mice died at an early age. As the mouse
knockout phenotype mimics the human PEHO phenotype this suggests that loss of CCDC88A is a cause of the PEHO phenotype,
and that CCDC88A is essential for multiple aspects of normal human neurodevelopment.
1 Cambridge Institute for Medical Research, University of Cambridge, Cambridge, CB2 0XY, UK
2 Department of Pathology, Centre for Neurological Disease and Cancer, Nagoya University Graduate School of Medicine, 65
Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466N, Japan
3 North West Thames Regional Genetics Service, Level 8V, London North West Healthcare NHS Trust, Watford Road, Harrow,
HA1 3UJ, UK
4 Department of Paediatric Neuroscience, Addenbrooke’s Hospital, Hills Rd, Cambridge, CB2 0QQ, UK
Correspondence to: C. Geoffrey Woods,
Cambridge Institute for Medical Research,
University of Cambridge, Cambridge, CB2 0XY, UK
E-mail: cw347@cam.ac.uk
Correspondence may also be addressed to:
Angela F. Brady,
North West Thames Regional Genetics Service, Level 8V,
London North West Healthcare NHS Trust, Watford Road, Harrow HA1 3UJ, UK
E-mail: angela.brady@nhs.net
Masahide Takahashi,
Department of Pathology, Centre for Neurological Disease and Cancer,
Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku,
doi:10.1093/brain/aww014 BRAIN 2016: 139; 1036–1044 | 1036
Received November 17, 2015. Revised December 09, 2015. Accepted December 23, 2015. Advance Access publication February 25, 2016
 The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.







Nagoya, Aichi 466-8550, Japan
E-mail: mtakaha@med.nagoya-u.ac.jp
Keywords: PEHO syndrome; girdin; neurodevelopmental disorder; epilepsy; microcephaly
Abbreviation: PEHO = progressive encephalopathy with oedema, hypsarrhythmia and optic atrophy
Introduction
Progressive encephalopathy with oedema, hypsarrhythmia
and optic atrophy (PEHO) syndrome is rare, of unknown
origin, and causes profound intellectual disability with little
if any developmental progress. It was ﬁrst described in
Finnish children in 1991, from where the most complete
phenotypic data originates (Salonen et al., 1991). Onset
occurs usually within the ﬁrst few weeks of life with affected
children displaying seizures, hypotonia and lack of visual
ﬁxation (Somer, 1993; D’Arrigo et al., 2005). Those affected
thence exhibit early arrest of motor and mental development,
optic atrophy, with radiological examination demonstrating
severe cerebellar and brainstem atrophy from birth, with
cerebral atrophy developing at a later stage (D’Arrigo et
al., 2005). Usually microcephaly is present at birth, but in-
evitably there is a progressive reduction in brain growth
(secondary microcephaly). Prognosis is poor with most pa-
tients dying before 10 years of age. Inheritance is predicted
to be autosomal recessive (Somer, 1993). Clinically there is
phenotypic overlap of PEHO syndrome with the early-in-
fantile epileptic encephalopathies (Cross and Guerrini,
2013). Cases lacking either optic atrophy or cerebellar hypo-
plasia are often termed PEHO-like (Chitty et al., 1996).
The genetic cause(s) and the underlying pathophysiology
of PEHO syndrome are unknown; and there is no known
curative therapy. We report a large consanguineous family
with three affected members in two nuclear families. In
affected individuals we identiﬁed a homozygous frameshift
mutation in CCDC88A, the gene that encodes the actin
binding protein girdin (GIRDers of actIN ﬁlament, also
known as APE GIV and HkPP) (Anai et al., 2005;
Enomoto et al., 2005; Le-Niculescu et al., 2005; Simpson
et al., 2005). We show that the mutation results in the
absence of full length, functional CCDC88A protein. To
further investigate the function of CCDC88A in mamma-
lian brain function we examined CCDC88A-deﬁcient mice
and compare their phenotype and CNS architecture to our
patients. Our results reveal novel insights into the under-
lying developmental, neuroanatomical and molecular de-
fects of CCDC88A deﬁciency in mammals.
Materials and methods
Materials and methods are described in detail in the
Supplementary material.
Subjects
The UK National Research Ethics Service, Cambridge Central
Research Ethics committee gave permission for our study. The
authors cared for the family for over a decade; all medical care
was within the National Health Service. Results and notes
were examined and recorded.
Exome sequencing
Genomic DNA from affected Patients 1 and 2 (Fig. 2A) was
extracted and analysed by exome sequencing (SureSelect
Human All Exon 50Mb Kit, Agilent Technologies).
Potentially pathogenic mutations were identiﬁed by compari-
son with the GRCh37 reference human genome, ﬁltering for
changes with allele frequencies of 5 1 in 500 in the 1000
Genomes project, and focused on homozygous changes affect-
ing both siblings. Any changes were conﬁrmed and tested for




To analyse possible nonsense mediated decay of mutant
CCDC88A, blood samples were taken from Patient 1 and their
parents, mRNA extracted and reverse transcribed to cDNA. Full
details of reverse transcription PCRs (RT-PCRs) undertaken and
primers used are detailed in the Supplementary material.
CCDC88A cloning and expression
CCDC88A cloned into the pCAGGS vector has been described
previously (Enomoto et al., 2005). The c.2313delT mutation
was introduced into the wild-type CCDC88A sequence by site-
directed mutagenesis using the QuikChange II Site-Directed
Mutagenesis kit (Agilent), and a haemagglutinin (HA) tag
added to the N-terminus. Expression of wild-type and
mutant proteins were analysed by western blot.
CCDC88A knockout mouse
The CCDC88A knockout mice and conditional Nestin–cre
knockout mice strains have been reported previously
(Kitamura et al., 2008; Asai et al., 2012). Full details of
brain dissection, staining and analysis are described in the
Supplementary material.
Results
Clinical features of the family
The clinical features of the affected children are summar-
ized in Table 1, and individual histories are given in the
Supplementary material.
All affected children presented at birth with microcephaly
[Occipito-frontal head circumference (OFHC) of  3
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standard deviation (SD) to 4 SD, typically 529 cm] and
moderately severe hypotonia. Weight and length at birth
were normal. Excepting the microcephaly, they were not
dysmorphic, nor did they have any extracranial congenital
anomalies. All spent 2–4 weeks in hospital until satisfactory
breathing and feeding were established. All developed seiz-
ures associated with anoxia presenting at birth or by 1
month. In all three subjects this progressed to ﬂexion in-
fantile spasms with hypsarrhythmia on EEG within the ﬁrst
year of life. Seizures became tonic/clonic by the third year,
ﬁts occurred frequently (at least weekly throughout life),
status epilepticus necessitating hospital admission at least
once in all three, and their seizures were persistently difﬁ-
cult to control necessitating frequent changes of medication
and dosage. Over the ﬁrst 6 months poor visual attention,
ﬁxing and following were noted, and all were diagnosed as
having severe cortical visual inattention. All had moderate
optic atrophy but otherwise a normal retina on fundo-
scopy; one had minor bilateral megalocornea (10mm at 6
months, but there were no associated problems from this,
such as glaucoma). Pufﬁness of the maxillary region of the
face, and the dorsum of the hands and feet was present
from birth, and persisted, but did not spread in extent
(Fig. 1). Over the ﬁrst 3 years of life it became clear that
all had profound cognitive delay. Severe motor delay was
also present with no development, with a combination of
central hypotonia and peripheral hypertonia. Thoraco-
lumbar kyphoscoliosis (with no vertebral anomalies) and
hip ﬂexion deformity developed by 3 years in two (the
third not being old enough). The degree of microcephaly
gradually increased over the years of follow up to 5 SD
to  6 SD by 3 years. MRI was performed on all three
affected children and showed the consistent and symmet-
rical ﬁndings shown in Fig. 1: widespread coarse pachy-
gyria with the posterior regions of the brain more
affected than anterior, polymicrogyria prominent in the
sylvian ﬁssures, dilated ventricles (reﬂecting brain substance
loss and not raised intraventricular pressure), hypoplastic
corpus callosum, subependymal cysts, and hypoplastic
pons. One of the three affected children had a small cere-
bellum shown on an MRI scan at 3 months.
The two families were related, and each set of parents
were ﬁrst cousins (Fig. 2). The parents were healthy, and of
normal cognitive and physical abilities, and had no abnor-
mal neurological features. The family were ethnic white
Caucasians. Each of the two families also had normal chil-
dren. In one family a deceased daughter had complete sex
reversal and absent adrenal glands, but no PEHO features.
No unusual events occurred in the pregnancy or delivery of
the affected children, nor was there any exposure to poten-
tial teratogens during the pregnancies. We concluded that
the condition was inherited as an autosomal recessive trait.
The affected children in this family fulﬁlled the diagnostic
criteria for PEHO syndrome; however, the presence of
structural brain anomalies (polymicrogyria nor pachygyria)
were not described in the original Finnish cases, and so we
considered that the better phenotypic diagnosis for the
family was PEHO-like syndrome.
Identification of CCDC88A mutation
To identify the causative gene mutation in this family,
exome analysis was performed on genomic DNA from
two affected children (Patients 1 and 2, Fig. 2A), the raw
sequences mapped to the GRCh37 reference human
genome, and any possible mutations shared in both chil-
dren analysed for their potential to cause PEHO syndrome.
We prioritized the search for mutations that would poten-
tially alter the encoded protein (nonsense/frameshift/splice
site/missense mutations), and to those that were both
homozygous and within concordant homozygous segments
shared between the two cousins. Only one deleterious mu-
tation was identiﬁed, which was present in both. This was
a homozygous frameshift mutation in the CCDC88A gene
(c.2313delT) creating a TAG stop codon at the site of the
frameshift (p.Leu772X) (Fig. 2B). Segregation of the muta-
tion was conﬁrmed by Sanger sequencing as homozygous in
all three affected children and heterozygous in all of their
parents (Fig. 2C). The mutation was not identiﬁed in the
1000 Genomes Project or ExAC database, and we did not
ﬁnd it in 4 200 ethnically matched control chromosomes
tested by Sanger sequencing.
CCDC88A encodes the actin binding protein girdin, which
has previously been demonstrated as a binding partner of Akt
and to play essential roles in the migration of ﬁbroblasts,
endothelial cells, cancer cells and neuronal cells (Enomoto et
al., 2005, 2009; Jiang et al., 2008; Kitamura et al., 2008).
Mice with germline deletion of girdin exhibit neuronal migra-
tion defects which result in hypoplasia of the olfactory bulb,
granule cell dispersion in the dentate gyrus and postnatal le-
thality, demonstrating a crucial role for girdin in the early
development of the mouse brain (Asai et al., 2012).
The girdin protein consists of a conserved N terminal
domain showing signiﬁcant homology to the microtubule
binding region of the Hook protein family and proposed
dimerization domain (Enomoto et al., 2006), a coiled coil
central domain, known to bind members of the G family
of heterotrimeric G proteins (Le-Niculescu et al., 2005) and
a C-terminal domain that speciﬁes binding partners includ-
ing actin and Akt (Fig. 2B) (Enomoto et al., 2006). We
hypothesized that the introduction of a premature stop
codon early within the coiled coil domain would likely
result in nonsense mediated decay and hence complete
loss of the translated product. However, we were unexpect-
edly able to identify a reduced amount of full length
mRNA, carrying the p.Leu772X in the lymphocytes of
Patient 1 (Fig. 2D and Supplementary Fig. 1), and were
able to exclude the possibility of abnormal splicing of the
exon containing the c.2313delT mutation (Supplementary
Fig. 1). While it is highly likely that this mutation would
nonetheless produce a complete knockout of the girdin pro-
tein, mRNA extracted from the brains of a Ccdc88a knock-
out mouse produced by excising exon 3 to produce a
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premature stop codon also displayed presence of the
mutated Ccdc88a transcript (Asai et al., 2012), we pro-
ceeded to conﬁrm the pathogenicity of the truncated
girdin by cloning it into HEK293 cells as a haemagglu-
tinin-tagged fusion protein. Wild-type girdin produced a
single band at 250kDa by western blot, whereas intro-
duction of the c.2313delT mutation by site-directed muta-
genesis resulted in a truncated product of around 105 kDa
in size (Fig. 2E). Many of girdin’s reported functions are
reliant on its interaction with C-terminal binding partners
(including actin, Par-3, Akt, multiple receptor tyrosine kin-
ases and Gi3; Enomoto et al., 2005, 2006; Ohara et al.,
2012; Lin et al., 2014; Bhandari et al., 2015) and its guan-
ine nucleotide exchange factor domain, membrane binding
region and a number of functional phosphorylatable resi-
dues lie downstream of the premature stop codon intro-
duced (Bhandari et al., 2015). It seems probable that, in
the unlikely event that the truncated protein is produced in
vivo, the function of the mutant protein would be highly
disrupted due to its absent C terminal functions.
Features of PEHO syndrome in
Ccdc88a knockout mice
Having proven the potential pathogenicity of the
p.Leu772X mutation in cellular models we asked if the
knockout of CCDC88A in the mouse might mimic features
of PEHO syndrome and could be used to identify molecu-
lar defects in the mouse brain responsible for the PEHO
phenotype, which are unable to be investigated in affected
humans. Mice with a knockout of CCDC88A have previ-
ously been reported to show a mesial-temporal lobe epi-
lepsy phenotype, and this was again found (Asai et al.,
2012). The mice also show postnatal lethality and postnatal
growth retardation being reported underweight at death
(Asai et al., 2012). This phenotype is generally consistent
with that of PEHO syndrome.
We proceeded to assess the brains of Ccdc88a deﬁcient
mice at an anatomical level. Completeness of corpus callo-
sum development in Ccdc88a deﬁcient mice was assessed
with Nissl stained coronal sections of neonatal (postnatal
Day 0) brain tissue. There was no global difference in ap-
pearance of corpus callosum between wild-type and
Ccdc88a deﬁcient mouse, while there was a signiﬁcant de-
velopmental defect in the caudal end of corpus callosum in
knockout mice (Fig. 3A–C). This may match the ﬁnding of
a hypoplastic corpus callosum observed in CCDC88A
mutant human patients. Layer structures of cerebrum at
postnatal Day 12 were compared between wild-type and
knockout using Kluver-Barrera staining and immunohisto-
chemistry with layer speciﬁc markers (Cux1 for layer II–III,
and Ctip2 for layer V). With Kluver-Barrera staining, no
‘polymicrocyria’ like lesions were observed.
Table 1 Diagnostic criteria for PEHO syndrome, with our clinical data and that of the Ccdc88a knockout mice








Infantile, usually neonatal hypotonia Yes Yes Yes Mice underweight (Asai et al., 2012)
Postnatal lethality (Asai et al., 2012)
Profound psychomotor retardation
with severe hypotonia: absence of motor
milestones and speech
Yes Yes Yes Not tested; however, we note possible
behavioural differences: Ccdc88a mice do
not hang upside down from the cage
like normal mice.
‘Mice were inactive, and
exhibited growth retardation and fatality
after P12’ (Asai et al., 2012)
Convulsive disorders presenting with myoclonic
jerking and infantile spasms
Yes Yes Yes Mesial-temporal lobe epilepsy phenotype
(Asai et al., 2012)
Absence or early loss of visual fixation with atrophy
of optic disc by 2 years of age
Yes Yes Yes No
Progressive brain atrophy in neuroimaging studies.
Particularly affecting the cerebellum and brain stem;
milder supratentorial atrophy
Yes Yes Yes Developmental defect in caudal end of
corpus callosum
Small cerebrum at postnatal Day 0
Supportive criteria
Subtle dysmorphic features including narrow fore-
head, epicanthic folds, short nose, open mouth,
receding
chin and tapering fingers
Yes Yes Yes N/A
Oedema of the face and limbs (early childhood) Yes Yes Yes Not identified
Brisk tendon reflexes (early childhood) Yes Yes Yes N/A
Absent cortical responses of somatorysensory
evoked potentials
Yes Not done Yes N/A
Slow nerve conduction velocities in late childhood Not done Not done Not done N/A
Dysmyelination in MRI Noa Noa Yes N/A
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Immunohistochemistry with layer markers didn’t detect any
abnormal layer structure, except that staining intensity of
Ctip2 was slightly less in knockout mice. To assess optic
nerve atrophy, the cross-section area of optic nerves were
measured with ImageJ (National Institute of Mental
Health, Bethesda, MD), and averaged. There was no sig-
niﬁcant difference between wild-type and knockout mice
(wild-type versus knockout, n = 6 versus 5, mean
0.0241017 versus 0.025981mm2, SD 0.003509 versus
0.003313mm2, t-test P-value 0.384). To assess microceph-
aly, analysis of overhead view pictures of brains from
nestin-Cre driven Ccdc88aﬂox/ﬂox mice (cKO) at postnatal
Day21 were carried out using ImageJ. Projected area of
cerebrum of cKO was signiﬁcantly smaller than that of
Ccdc88a wild-type/ﬂox nestin-Cre (-) (control), while
areas of cerebellum of cKO and control were similar (Fig.
3D and E).
Discussion
We investigated a multi-affected consanguineous family of
British origin with three children born with features of
PEHO syndrome. By comparing the exomes of consanguin-
eous ﬁrst cousins we detected a single nucleotide deletion in
exon 15 of CCDC88A (c.2313delT). This results in a
frameshift and incorporation of a stop codon
(p.Leu772X). Our results conﬁrm an autosomal recessive
pattern of inheritance for PEHO syndrome, and identify
CCDC88A as a further gene essential for normal human
brain development.
CCDC88A encodes the actin binding protein girdin, a
multi-domain, non-receptor guanine exchange factor
(GEF) for G proteins Gi1, G2 and G3, which has
been attributed a wide range of functions including roles
in cell migration and Akt/EGFR signalling (Enomoto et al.,
2006; Beas et al., 2012; Bhandari et al., 2015), actin or-
ganization and cell motility (Enomoto et al., 2005), neurite
outgrowth and migration, axon/dendrite development
(Enomoto et al., 2009; Wang et al., 2011) and to regulate
early endosome maturation (Beas et al., 2012). Girdin can
link actin ﬁlaments through its C terminal domain and
simultaneously bind the plasma membrane through the ad-
jacent membrane binding domain at the protein C ter-
minus. This allows girdin to function in actin cytoskeletal
remodelling during cell mobility (Hu et al., 2015). Other
genes reported to cause cortical lamination defects (lissen-
cephaly, pachygyria and polymicrogryia), severe develop-
mental delay and seizures, are also generally cytoskeletal
proteins (e.g. the tubulins) or act upon cytoskeletal proteins
[LIS1 (PAFAH1B1), DCX, reelin (RELN), NUDE (NDE1)
and NDEL1], and similar to CCDC88A, have complex
multiple interactions, and functions (Guerrini and
Dobyns, 2014).
Figure 1 Clinical features of PEHO syndrome caused by CCDC88A truncating mutation. (A) Brain scans of affected patients. [A(i
and ii)] T1- and T2-weighted axial images; [A(iii)] T1 SENSE coronal images. All demonstrate reduced brain volume with bilateral, severe
pachygyria/lissencephaly. [A(iv)] represents a T2-weighted TIRM sagittal image demonstrating a thin corpus callosum and mild reduction in
cerebellar vermis volume. [B(i and ii)] Characteristic faces with apparent swollen cheeks, narrow sloping forehead and microcephaly. [B(iii)]
Typical oedema of the dorsum of the hand. [B(iv)] Typical pedal oedema of PEHO syndrome. Images are of the proband Patient 1 at age 6 years.
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Postnatally, girdin is expressed in the majority of mam-
malian tissues; however, during embryonic development,
the expression pattern of CCDC88A is speciﬁcally re-
stricted, both spatially and temporally to regions of the
fore-, mid- and hindbrain as well as the dorsal root ganglia,
somites, limbs, nasal processes and branchial arches
(Simpson et al., 2005). This speciﬁc expression proﬁle
implies a potentially important role during embryonic
development.
The identiﬁcation of a truncating mutation in CCDC88A
in individuals with PEHO syndrome conﬁrms a crucial
function for girdin during embryonic development.
Patients with a mutation in CCDC88A resulting in either
a truncated girdin or absence of the protein due to
Figure 2 Discovery of a c.2313delT/p.Leu772X mutation in CCDC88A in individuals with PEHO syndrome. (A) Family pedigree
with both sets of parents being first cousins. The filled in symbols indicate the three affected children; ‘1’ was the proband. (B) Schematic diagram
of the CCDC88A gene on chromosome 2, and girdin protein with its known functional domains annotated. The c.2313delT mutation occurs in
exon 15 and causes a nonsense mutation producing a truncated protein product lacking the membrane binding and actin binding domains of girdin.
(C) Electrophoretograms of an unaffected control, carrier parent and affected child with the p.Leu772X mutation. (D) Reverse transcriptase
polymerase chain reaction amplifying the mutant cDNA transcript from mRNA extracted from the lymphocytes of affected Patient 1 and his
parents. (E) Western blot probed for haemagglutinin (HA), demonstrating the truncated product of CCDC88A harbouring the c.2313delT
mutation.
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Figure 3 Ccdc88a-deficient neonatal mice (postnatal Day 0) exhibit mild hypoplastic defect in the caudal end of corpus callosum at
midline. (A) Paraffin embedded brain tissues from wild-type mice (WT) or straight Ccdc88a deficient mice (KO) were coronally sectioned at 7-mm
thickness. All sections were serially numbered using the rostral end of hippocampus as a reference section. Rostral sections are positively numbered, and
caudal sections were negatively numbered. (B) Nissl stained coronal sections of wild-type and knockout brain. Positions of corpus callosum (CC) relative
to the rostral end of hippocampus were similar between wild-type and knockout mice (at around +120 section), while the caudal end of knockout mice
corpus callosum was relatively displaced forward compared with the caudal end of wild-type corpus callosum (wild-type at around 20 section level,
knockout at around the reference section). hipp = rostral end of hippocampus. Black square indicates the area of each inset at bottom right corner. (C)
Statistical analysis of positions of corpus callosum relative to the rostral end of hippocampus. Three replicates from each genotype were analysed. Section
numbers of the rostral end of corpus callosum from the reference section were averaged. In accordance with the observations in B, the caudal ends of
corpus callosum of knockout were significantly displaced to rostral side. Values are shown as mean plus standard error. T-test P values less than 0.05 were
considered significant. (D) Overhead view of Ccdc88a wild-type/flox:nestin-Cre() control mouse (Con) and Ccdc88a flox/flox:nes-Cre( + ) conditional
knockout mouse (cKO). (E) Horizontal projected area was measured and analysed. Cerebrum of cKO was significantly smaller than control mice, while
areas of cerebellum were not different between controls and cKO mice.
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nonsense mediated decay, displayed all of the necessary
clinical criteria to be diagnosed with PEHO syndrome.
All presented at birth with microcephaly and moderately
severe hypotonia and developed seizures that progressed
into infantile spasms with hypsarrhythmia on EEG. All
also displayed progressive brain atrophy, optic atrophy,
severe cognitive delay and pufﬁness of the maxillary
region of the face, and the dorsum of the hands and feet.
Reassessment of knockout mice for Ccdc88a demonstrated
further conﬁrmation of CCDC88A as a PEHO-causing
gene, with mice displaying a similar phenotype with
mesial-temporal lobe epilepsy and early demise, and struc-
tural brain developmental defects affecting the corpus cal-
losum and cerebrum. A lack of macroscopic pachygyria
was expected as the murine cerebral cortex is ‘smooth’
and without a gyral pattern. However, the ﬁnding of
only a minor (layer 5) cortical lamination defects in
Ccdc88a mice may have been unexpected; the human/
mouse correlations for other similar brain–cytoskeletal
genes are variable and unexplained: e.g. DCX mutations
cause pachygyria in humans and the knockout mouse
shows only hippocampal lamination defects (des Portes et
al., 1998; Corbo et al., 2002); NDE1 mutations cause lis-
sencephaly in humans and the knockout mouse has micro-
cephaly, but cortical lamination is mostly preserved (Feng
and Walsh, 2004; Wynshaw-Boris et al., 2010).
Recently, an individual with PEHO syndrome was re-
ported who harboured a de novo missense mutations in
KIF1A, and the authors noted up to six similar previously
reported cases (Langlois et al., 2015). Of other individuals
with signiﬁcant mental handicap and KIF1A missense mu-
tations, most had prominent and progressive spasticity and
neuropathy—ﬁndings atypical of PEHO syndrome
(Okamoto et al., 2014; Esmaeeli Nieh et al., 2015; Lee et
al., 2015; Ohba et al., 2015). Furthermore, KIF1A muta-
tions have also been reported to cause dominant and reces-
sive pure spastic paraplegia, recessive sensory neuropathy
and dominant mental retardation (OMIM: 601255). Thus,
the PEHO syndrome phenotype can also have a dominant,
and not just a recessive, inheritance pattern caused by a
subset of KIF1A missense mutations.
To conclude, we report the ﬁrst identiﬁcation of a gene,
CCDC88A, which when mutated causes an autosomal re-
cessive PEHO-like neurodevelopmental phenotype. We
detail the human phenotype caused by the lack of function-
ing GIRDIN, and found similar neurological features and
anatomy in CCDC88A knockout mouse.
Funding
This work was supported by the MRC and Cambridge
University Hospitals NHS Foundation Trust (M.S.N.).
Y.C.C. and C.G.W. are supported by the Cambridge
NIHR Biomedical Research Centre. This work was also
supported by A-STEP from the Japan Science and
Technology Agency in 2014 (AS251Z02522Q) and in
2015 (AS262Z00715Q), a Takeda Visionary Research
Grant 2014 from the Takeda Science Foundation, a
Grant-in-Aid for Scientiﬁc Research (C) (to M.A.), and a
Grant-in-Aid for Scientiﬁc Research (S) (to M.T.) from the
Ministry of Education, Culture, Sports, Science, and
Technology in Japan.
Supplementary material
Supplementary material is available at Brain online.
References
Anai M, Shojima N, Katagiri H, Ogihara T, Sakoda H, Onishi Y,
et al. A novel protein kinase B (PKB)/AKT-binding protein enhances
PKB kinase activity and regulates DNA synthesis. J Biol Chem 2005;
280: 18525–35.
Asai M, Asai N, Murata A, Yokota H, Ohmori K, Mii S, et al. Similar
phenotypes of Girdin germ-line and conditional knockout mice in-
dicate a crucial role for Girdin in the nestin lineage. Biochem
Biophys Res Commun 2012; 426: 533–8.
Beas AO, Taupin V, Teodorof C, Nguyen LT, Garcia-Marcos M,
Farquhar MG. Galphas promotes EEA1 endosome maturation and
shuts down proliferative signaling through interaction with GIV
(Girdin). Mol Biol Cell 2012; 23: 4623–34.
Bhandari D, Lopez-Sanchez I, To A, Lo IC, Aznar N, Leyme A, et al.
Cyclin-dependent kinase 5 activates guanine nucleotide exchange
factor GIV/Girdin to orchestrate migration-proliferation dichotomy.
Proc Natl Acad Sci USA 2015; 112: E4874–83.
Chitty LS, Robb S, Berry C, Silver D, Baraitser M. PEHO or PEHO-
like syndrome? Clin Dysmorphol 1996; 5: 143–52.
Corbo JC, Deuel TA, Long JM, LaPorte P, Tsai E, Wynshaw-Boris A,
et al. Doublecortin is required in mice for lamination of the hippo-
campus but not the neocortex. J Neurosci 2002; 22: 7548–57.
Cross JH, Guerrini R. The epileptic encephalopathies. Handbook Clin
Neurol 2013; 111: 619–26.
D’Arrigo S, Grazia BM, Faravelli F, Riva D, Pantaleoni C. Progressive
encephalopathy with edema, hypsarrhythmia, and optic nerve atro-
phy (PEHO)-like syndrome: what diagnostic characteristics are
deﬁning? J Child Neurol 2005; 20: 454–6.
des Portes V, Pinard JM, Billuart P, Vinet MC, Koulakoff A, Carrie A,
et al. A novel CNS gene required for neuronal migration and
involved in X-linked subcortical laminar heterotopia and lissence-
phaly syndrome. Cell 1998; 92: 51–61.
Enomoto A, Asai N, Namba T, Wang Y, Kato T, Tanaka M, et al.
Roles of disrupted-in-schizophrenia 1-interacting protein girdin in
postnatal development of the dentate gyrus. Neuron 2009; 63:
774–87.
Enomoto A, Murakami H, Asai N, Morone N, Watanabe T, Kawai K,
et al. Akt/PKB regulates actin organization and cell motility via
Girdin/APE. Dev Cell 2005; 9: 389–402.
Enomoto A, Ping J, Takahashi M. Girdin, a novel actin-binding pro-
tein, and its family of proteins possess versatile functions in the Akt
and Wnt signaling pathways. Ann N Y Acad Sci 2006; 1086:
169–84.
Esmaeeli Nieh S, Madou MR, Sirajuddin M, Fregeau B, McKnight D,
Lexa K, et al. De novo mutations in KIF1A cause progressive en-
cephalopathy and brain atrophy. Ann Clin Transl Neurol 2015; 2:
623–35.
Feng Y, Walsh CA. Mitotic spindle regulation by Nde1 controls cere-
bral cortical size. Neuron 2004; 44: 279–93.
CCDC88A mutations cause PEHO-like syndrome BRAIN 2016: 139; 1036–1044 | 1043







Guerrini R, Dobyns WB. Malformations of cortical development: clin-
ical features and genetic causes. The Lancet Neurology 2014; 13:
710–26.
Hu JT, Li Y, Yu B, Gao GJ, Zhou T, Li S. Girdin/GIV is upregulated
by cyclic tension, propagates mechanical signal transduction, and is
required for the cellular proliferation and migration of MG-63 cells.
Biochem Biophys Res Commun 2015; 464: 493–9.
Jiang P, Enomoto A, Jijiwa M, Kato T, Hasegawa T, Ishida M, et al.
An actin-binding protein Girdin regulates the motility of breast
cancer cells. Cancer Res 2008; 68: 1310–8.
Kitamura T, Asai N, Enomoto A, Maeda K, Kato T, Ishida M, et al.
Regulation of VEGF-mediated angiogenesis by the Akt/PKB sub-
strate Girdin. Nat Cell Biol 2008; 10: 329–37.
Langlois S, Tarailo-Graovac M, Sayson B, Drogemoller B, Swenerton
A, Ross CJ, et al. De novo dominant variants affecting the motor
domain of KIF1A are a cause of PEHO syndrome. Eur J Hum Genet
2015;
Le-Niculescu H, Niesman I, Fischer T, DeVries L, Farquhar MG
Identiﬁcation and characterization of GIV, a novel Galpha i/s-inter-
acting protein found on COPI, endoplasmic reticulum-Golgi trans-
port vesicles. J Biol Chem 2005; 280: 22012–20.
Lee JR, Srour M, Kim D, Hamdan FF, Lim SH, Brunel-Guitton C,
et al. De novo mutations in the motor domain of KIF1A cause
cognitive impairment, spastic paraparesis, axonal neuropathy, and
cerebellar atrophy. Hum Mut 2015; 36: 69–78.
Lin C, Ear J, Midde K, Lopez-Sanchez I, Aznar N, Garcia-Marcos M,
et al. Structural basis for activation of trimeric Gi proteins by
multiple growth factor receptors via GIV/Girdin. Mol Biol Cell
2014; 25: 3654–71.
Ohara K, Enomoto A, Kato T, Hashimoto T, Isotani-Sakakibara M,
Asai N, et al. Involvement of Girdin in the determination of cell
polarity during cell migration. PLoS One 2012; 7: e36681.
Ohba C, Haginoya K, Osaka H, Kubota K, Ishiyama A, Hiraide T,
et al. De novo KIF1A mutations cause intellectual deﬁcit, cerebellar
atrophy, lower limb spasticity and visual disturbance. J Hum Genet
2015;
Okamoto N, Miya F, Tsunoda T, Yanagihara K, Kato M, Saitoh S,
et al. KIF1A mutation in a patient with progressive neurodegenera-
tion. J Hum Genet 2014; 59: 639–41.
Salonen R, Somer M, Haltia M, Lorentz M, Norio R. Progressive
encephalopathy with edema, hypsarrhythmia, and optic atrophy
(PEHO syndrome). Clin Genet 1991; 39: 287–93.
Simpson F, Martin S, Evans TM, Kerr M, James DE, Parton RG, et al.
A novel hook-related protein family and the characterization of
hook-related protein 1. Trafﬁc 2005; 6: 442–58.
Somer M. Diagnostic criteria and genetics of the PEHO syndrome. J
Med Genet 1993; 30: 932–6.
Wang Y, Kaneko N, Asai N, Enomoto A, Isotani-Sakakibara M, Kato
T, et al. Girdin is an intrinsic regulator of neuroblast chain migra-
tion in the rostral migratory stream of the postnatal brain. J
Neurosci 2011; 31: 8109–22.
Wynshaw-Boris A, Pramparo T, Youn YH, Hirotsune S.
Lissencephaly: mechanistic insights from animal models and poten-
tial therapeutic strategies. Semin Cell Dev Biol 2010; 21: 823–30.
1044 | BRAIN 2016: 139; 1036–1044 M. S. Nahorski et al.
 by guest on O
ctober 14, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
